
## Claims

July A21 1

- Use of a D- or L-tryptophanyl-ester or its N-acyl derivative for producing a pharmaceutical composition for the prophylaxis and therapy of oxidative pathologic processes in degenerative diseases and/or cancer diseases.
- 2. Use according to claim 1, wherein the b- or L-tryptophanyl-ester or its N-acyl derivative is the following substance:

tryptophanoctyl-ester, tryptophanodecyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophanodecyl-ester, N-acetyl-tryptophanodecyl-ester, N-acetyl-tryptophanodecyl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophanotyl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester, N-palmitoyl-tryptophanethyl-ester or N-oleoyl-tryptophanethyl-ester.

- 3. Use according to claim 1, wherein the D- or L-tryptophanethyl-ester or its N-acetyl derivative is tryptophanectyl-ester, N-oleoyl-tryptophanethyl-ester or N-dodecanoyl-tryptophanethyl-ester.
- 4. Use according to any one of claims 1 to 3 for the treatment and or prophylaxis of neurodegenerative diseases.
- 5. Use according to claim 4, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, apoplectic fit or amyotrophic lateral sclerosis.
- 6. Use according to any one of claims 1 to 3 for the treatment and/or prophylaxis of cataracts.
- 7. Use according to claim 6, wherein the cataract is Cataracta senilis, Cataracta juvenilis, Cataracta diabetica or Cataracta complicata.
- 8. Use according to any one of claims 1 to 3 for the treatment and/or prophylaxis of neoplastic diseases.



- 10. Use according to any one of claims 1 to 3 for the treatment and/or prophylaxis of cardiovascular diseases
- 11. Use according to claim 10, wherein the cardiovascular disease is arteriosclerosis or a myocardial infarction.
- 12. Pharmaceutical composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative according to any one of claims 1 to 3 for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases and, optionally, a pharmaceutically acceptable carrier, alone or in combination with other antioxidatively effective pharmaceutical compositions or pharmaceutical/compositions used with degenerative and/or cancer diseases.
- 13. Use for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases comprising the administration of a prophylactic or therapeutic amount of a D- or L-tryptophanyl-ester or its N-acyl derivative according to any one of claims 1 to 3.

app Ct